Assessing prognosis in cholangiocarcinoma: a review of promising genetic markers and imaging approaches

References

• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinoma–a population-based study. Ann Surg Oncol. 2008 Feb;15(2):600–608.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Kim Y, Ejaz A, et al. Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg. 2015 Jun;150(6):538–545.
   PubMed Web of Science ®Google Scholar
• Bagante F, Spolverato G, Merath K, et al. Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery. 2019 Dec;166(6):983–990.
   PubMed Web of Science ®Google Scholar
• Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008 Jul;248(1):84–96.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Bagante F, Ethun CG, et al. Defining the chance of statistical cure among patients with extrahepatic biliary tract cancer. World J Surg. 2017 Jan;41(1):224–231.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Bagante F, Ardito F, et al. Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma. Surgery. 2018 Aug;164(2):244–250.
   PubMed Web of Science ®Google Scholar
• Conci S, Ruzzenente A, Vigano L, et al. Patterns of distribution of hepatic nodules (Single, satellites or multifocal) in intrahepatic cholangiocarcinoma: prognostic impact after surgery. Ann Surg Oncol. 2018 Nov;25(12):3719–3727.
   PubMed Web of Science ®Google Scholar
• Bagante F, Spolverato G, Weiss M, et al. Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017 Sep;24(9):2491–2501.
   PubMed Web of Science ®Google Scholar
• Bagante F, Merath K, Squires MH, et al. The limitations of standard clinicopathologic features to accurately risk-stratify prognosis after resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2018 Mar;22(3):477–485.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Squires MH 3rd, Bagante F, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Ann Surg Oncol. 2018 May;25(5):1140–1149.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017 Oct;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Bagante F, Ruzzenente A, Conci S, et al. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? HPB (Oxford). 2019 Dec;21(12):1648–1655.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3;5:4006.
   PubMed Web of Science ®Google Scholar
• Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013 Jul;44(7):1216–1222.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017 Mar 14;18(11):2780–2794.
   PubMed Web of Science ®Google Scholar
• Fouassier L, Marzioni M, Afonso MB, et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019 May;39(Suppl 1):43–62.
   PubMed Web of Science ®Google Scholar
• Bai HX, Lee AM, Yang L, et al. Imaging genomics in cancer research: limitations and promises. Br J Radiol. 2016;89(1061):20151030.
   PubMed Web of Science ®Google Scholar
• Pinker K, Shitano F, Sala E, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging. 2018 Mar;47(3):604–620.
   PubMed Web of Science ®Google Scholar
• Jeong WK, Jamshidi N, Felker ER, et al. Radiomics and radiogenomics of primary liver cancers. Clin Mol Hepatol. 2019 Mar;25(1):21–29.
   PubMed Web of Science ®Google Scholar
• Louis C, Papoutsoglou P, Coulouarn C. Molecular classification of cholangiocarcinoma. Curr Opin Gastroenterol. 2020 Mar;36(2):57–62.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Fassan M, Conci S, et al. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016 May;23(5):1699–1707.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014 Nov;21(12):3827–3834.
   PubMed Web of Science ®Google Scholar
• Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012 Oct;43(10):1552–1558.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014 Mar;19(3):235–242.
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014 Aug;45(8):1630–1638.
   PubMed Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. 2018;3:1–12.
   PubMed Web of Science ®Google Scholar
• Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018 May;68(5):959–969.
   PubMed Web of Science ®Google Scholar
• Conci S, Ruzzenente A, Simbolo M, et al. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. Updates Surg. 2020 Mar;72(1):119–128.
   PubMed Web of Science ®Google Scholar
• Xue L, Guo C, Zhang K, et al. Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr. 2019 Dec;8(6):615–622.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015 Sep;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Dozmorov MG, Giles CB, Koelsch KA, et al. Systematic classification of non-coding RNAs by epigenomic similarity. BMC Bioinformatics. 2013;14(Suppl 14):S2.
   PubMedGoogle Scholar
• Salati M, Braconi C. Noncoding RNA in Cholangiocarcinoma. Semin Liver Dis. 2019 Feb;39(1):13–25.
   PubMed Web of Science ®Google Scholar
• Han L, Zhang EB, Yin DD, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 2015 Feb 26;6:e1665.
   PubMed Web of Science ®Google Scholar
• Angenard G, Merdrignac A, Louis C, et al. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Dig Liver Dis. 2019 Sep;51(9):1337–1343.
   PubMedGoogle Scholar
• Qin W, Kang P, Xu Y, et al. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma. Sci Rep. 2018 Aug 15;8(1):12176.
   PubMedGoogle Scholar
• Yu Y, Chen Q, Zhang X, et al. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression. Cancer Sci. 2020 May 7;5(8):2276–2292.
   Web of Science ®Google Scholar
• Zheng B, Jeong S, Zhu Y, et al. miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA). Oncotarget. 2017 Nov 21;8(59):100819–100830.
   PubMedGoogle Scholar
• Li L, Piontek K, Ishida M, et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017 Feb;65(2):501–514.
   PubMed Web of Science ®Google Scholar
• Julich-Haertel H, Urban SK, Krawczyk M, et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol. 2017 Aug;67(2):282–292.
   PubMed Web of Science ®Google Scholar
• Xie F, Feng S, Yang H, et al. Extracellular vesicles in hepatocellular cancer and cholangiocarcinoma. Ann Transl Med. 2019 Mar;7(5):86.
   PubMed Web of Science ®Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012 Dec;2(12):1118–1133.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018 Jan 20;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015 Oct 20;33(30):3401–3408.
   PubMed Web of Science ®Google Scholar
• Dabney RS, Khalife M, Shahid K, et al. Molecular pathways and targeted therapy in cholangiocarcinoma. Clin Adv Hematol Oncol. 2019 Nov;17(11):630–637.
   PubMed Web of Science ®Google Scholar
• Necchi A, Pouessel D, Leibowitz-Amit R, et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Ann Oncol. 2018;29:viii319–viii320.
   Web of Science ®Google Scholar
• Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb;10(2):e1004135.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Javle M, Kelley RK, et al. LBA10_PR - ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol. 2019;30:2.
   Web of Science ®Google Scholar
• Fabrega-Foster K, Ghasabeh MA, Pawlik TM, et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017 Apr;6(2):67–78.
   PubMed Web of Science ®Google Scholar
• Madhusudhan KS, Gamanagatti S, Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: A review. World J Radiol. 2015 Feb 28;7(2):28–44.
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013 Jan;11(1):13–21e1; quiz e3-4.
   PubMed Web of Science ®Google Scholar
• Ruys AT, van Beem BE, Engelbrecht MR, et al. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 2012 Sep;85(1017):1255–1262.
   PubMed Web of Science ®Google Scholar
• Zandrino F, Benzi L, Ferretti ML, et al. Multislice CT cholangiography without biliary contrast agent: technique and initial clinical results in the assessment of patients with biliary obstruction. Eur Radiol. 2002 May;12(5):1155–1161.
   PubMed Web of Science ®Google Scholar
• Hamaoka M, Kozaka K, Matsui O, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol. 2019 Oct;37(10):669–684.
   PubMed Web of Science ®Google Scholar
• Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol. 2016 Feb;26(2):407–416.
   PubMed Web of Science ®Google Scholar
• Patyk M, Silicki J, Mazur R, et al. Radiomics - the value of the numbers in present and future radiology. Pol J Radiol. 2018;83:e171–e174.
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Kinahan PE, Radiomics: HH. Images are more than pictures, they are data. Radiology. 2016 Feb;278(2):563–577.
   PubMed Web of Science ®Google Scholar
• Parekh V, Jacobs MA. Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev. 2016;1(2):207–226.
   PubMed Web of Science ®Google Scholar
• Avanzo M, Stancanello J, El Naqa I. Beyond imaging: the promise of radiomics. Phys Med. 2017 Jun;38:122–139.
   PubMed Web of Science ®Google Scholar
• Meng Y, Sun J, Qu N, et al. Application of radiomics for personalized treatment of cancer patients. Cancer Manag Res. 2019;11:10851–10858.
   PubMed Web of Science ®Google Scholar
• Ji GW, Zhang YD, Zhang H, et al. Biliary tract cancer at CT: a radiomics-based model to predict lymph node metastasis and survival outcomes. Radiology. 2019 Jan;290(1):90–98.
   PubMed Web of Science ®Google Scholar
• Ji GW, Zhu FP, Zhang YD, et al. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol. 2019 Jul;29(7):3725–3735.
   PubMed Web of Science ®Google Scholar
• Mazurowski MA. Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015 Aug;12(8):862–866.
   PubMed Web of Science ®Google Scholar
• Kuo MD, Jamshidi N. Behind the numbers: decoding molecular phenotypes with radiogenomics–guiding principles and technical considerations. Radiology. 2014 Feb;270(2):320–325.
   PubMed Web of Science ®Google Scholar
• Lo Gullo R, Daimiel I, Morris EA, et al. Combining molecular and imaging metrics in cancer: radiogenomics. Insights Imaging. 2020 Jan 3;11(1):1.
   PubMed Web of Science ®Google Scholar
• Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009 May;70(2):232–241.
   PubMed Web of Science ®Google Scholar
• Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012 Mar;48(4):441–446.
   PubMed Web of Science ®Google Scholar
• Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012 Nov;30(9):1234–1248.
   PubMed Web of Science ®Google Scholar
• Morin O, Vallieres M, Jochems A, et al. A deep look into the future of quantitative imaging in oncology: a statement of working principles and proposal for change. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1074–1082.
   PubMed Web of Science ®Google Scholar
• Kiryu S, Akai H, Nojima M, et al. Impact of hepatocellular carcinoma heterogeneity on computed tomography as a prognostic indicator. Sci Rep. 2017 Oct 4;7(1):12689.
   PubMedGoogle Scholar
• Sadot E, Simpson AL, Do RK, et al. Cholangiocarcinoma: correlation between molecular profiling and imaging phenotypes. PLoS One. 2015;10(7):e0132953.
   PubMed Web of Science ®Google Scholar
• Aherne EA, Pak LM, Goldman DA, et al. Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics? Abdom Radiol (NY). 2018 Oct;43(10):2665–2672.
   PubMed Web of Science ®Google Scholar
• Yang C, Huang M, Li S, et al. Radiomics model of magnetic resonance imaging for predicting pathological grading and lymph node metastases of extrahepatic cholangiocarcinoma. Cancer Lett. 2020 Feb;1(470):1–7.
   Google Scholar
• Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern–correlation with clinicopathologic findings. Radiology. 2011 Jul;260(1):148–157.
   PubMed Web of Science ®Google Scholar
• Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Radiol. 2017 Feb;27(2):498–506.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim SH, Kang TW, et al. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology. 2016 Oct;281(1):119–128.
   PubMed Web of Science ®Google Scholar